Acting as an advance treatment for esophageal cancer.

Esophageal cancer is seventh most common cancer, which causes death across the world. This cancer is 4 times more common in men than women, because it is estimated that approx 18,170 new cases of this cancer is diagnosed in which 14,660 cases is found in men,while 3,510 cases is found in women, in 2014. Now, researchers are developing advanced immunotherapeutic agents like monoclonal antibodies (MABs), vaccines, adoptive T cell therapy, checkpoint inhibitors, cytokines and adjuvant immunotherapy by new technology for treatment of this cancer.

 

www.gapsos.com

Yet, not a single immunotherapeutic agent has received approval by the Food and Drug Administration (FDA) for treatment of esophageal cancer, but many are under the way of clinical trials for approval by FDA.

MABs targets to specific tumour cells. IMMU-132 (NCT01631552) that is an antibody drug conjugate containing the humanized MAB, which targets to tumor associated calcium signal transducer 2 (TACSTD2), is running in phase I and II of clinical trials under safety and efficacy study.

Vaccines based immunotherapy, enhancing the potential of the body’s immune system to fight with this cancer.Aldesleukin (NCT01697527) that is a vaccine targets to a specific antigen, which is running in phase II under safety and efficacy study.

Adoptive cell therapy is done by using of Tumor Infiltrating Lymphocytes (TIL) and Anti-MAGE A3-DP4 TCR for the treatment of this disease.Tumor Infiltrating Lymphocytes (NCT01174121) is targeting for growth of specific tumor cells, which is running in phase II under non randomized and efficacy study.

Checkpoint controls the regulation of the body’s immune response. MK-3475 (NCT02054806), that is a checkpoint inhibitor targets to programmed death- ligand 1 (PD-L1), which is running in phase I under efficacy study.

Cytokines control the growth of the body’s immune system.rh IL-15 (NCT01572493) that is a cytokine, which stimulate the immune system, is running in phase I under safety study.

In adjuvant, Ligand based immune oncology can be work as stimulation of agonist or inhibition of antagonist.CBLB502 (NCT01527136) that is adjuvant targets to inhibition of growth of specific tumor cells, which is running in phase I under safety study.

Global Allied pharmaceuticals (GAP) has new technology for the development of advance therapy, including immunotherapy and immune combination therapy for the treatment of various types of cancer disease that involves esophageal cancer and much more. GAP has own community of researchers, who conducts the experiments and clinical trials of new immunotherapeutic agents.

For more information kindly contact us at www.gapsos.com